Posthemorrhagic hydrocephalus of prematurity (PHHP) remains a substantial public health concern. Defined by symptomatic accumulation of cerebrospinal fluid (CSF) concomitant with elevated intracranial pressure (ICP) secondary to intraventricular hemorrhage (IVH), PHHP is a severe manifestation of encephalopathy of prematurity and a significant contributor to the global burden of prematurity and acquired hydrocephalus1,2. Globally, approximately 400,000 infants each year are born with or acquire the lifelong burden of hydrocephalus3 and many die due to lack of treatment3. PHHP is common in developed countries in very preterm infants (<32 weeks' gestation) with severe IVH, and often affects the sickest of infants who are already suffering from other life-threatening co-morbidities4,5.
The only available treatment for hydrocephalus is surgery6. Surgical procedures yield better longevity when infants are older than 6 months at the time of the first permanent intervention, whether for a ventriculoperitoneal (VP) shunt to divert cerebrospinal fluid (CSF), endoscopic third ventriculostomy (ETV), or ETV with choroid plexus coagulation (ETV-CPC)7. The most common option, VP shunts, often fail within a year and predispose children to a lifetime of complications, repeat surgeries, and hospitalizations at a tremendous cost to the child, the family, and society.8 In particular, the anxiety from a shunt potentially failing at any time is burdensome to families9. Care for children with symptomatic hydrocephalus, including frequent surgeries, is a leading cause of pediatric healthcare expenditures10,11,12,13,14. The annual estimated cost for shunt-related expenditures in children was $2 billion in 200315. While children with shunts comprise only 0.6% of hospital admissions, they generate 3.1% of pediatric hospital charges15. Thus, the discovery of safe, non-surgical therapies for the treatment of PHHP is paramount.
In infants, PHHP develops after IVH over a clinical time course that lasts weeks to months after the initial identification of the brain bleed. A study conducted by the Hydrocephalus Clinical Research Network (HCRN) confirmed that VP shunts remain the best surgical option for neonates with PHHP16. Even for children with PHHP in high-income countries with access to skilled pediatric neurosurgical care, outcomes are far from optimal, with >50% of shunts placed in infants with PHHP requiring surgical revision within the first 2 years8. Despite the clear need to identify safer, more effective treatments for PHHP, research has faced obstacles. Progress has been hampered in part because the preclinical literature on PHHP often fails to appropriately distinguish ventriculomegaly caused by hydrocephalus ex vacuo17,18 from symptomatic hydrocephalus with macrocephaly19,20. Indeed, developmental models of hydrocephalus should include progressive macrocephaly and/or measurements of elevated ICP1.
Merging clinical and preclinical insights has improved study design and propelled our understanding of PHHP2. Studies conducted in diverse centers throughout the globe have shown that IVH is most common in very preterm neonates secondary to chorioamnionitis21,22,23,24,25,26,27,28. In addition to placental infection and inflammation, neonatal sepsis is an additional important risk factor and can play a central role in the progression from IVH to ventriculomegaly to symptomatic PHHP and subsequent surgical intervention29. Preclinical and clinical data support that blood-borne inflammation can cause hydrocephalus20, and systemic inflammation increases secretion of CSF by the choroid plexus30. Further, adults with subarachnoid hemorrhage and IVH who also suffer from sepsis are much more likely to require a shunt31. More recent literature has confirmed that inflammation reduces ependymal motile cilia propulsion of CSF19,20,32 and CSF reabsorption by the glymphatic system33,34,35,36. Overall, systemic inflammation is a key pathophysiological and clinical driver in PHHP1.
Considering these findings, we created an age-appropriate preclinical model of PHHP. This model combines IVH in the immediate and early postnatal period with chorioamnionitis, the principal cause of preterm birth19. This experimental approach begins in utero, with the placental insufficiency, placental inflammation, and intraamniotic inflammation that defines chorioamnionitis7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22,
23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,
43,44,45. Specifically, we recapitulate a fetal inflammatory response syndrome, placental neutrophilia, and proinflammatory CNS microenvironment in the preterm period via abdominal laparotomy in pregnant rat dams on embryonic day 18 (E18)37,38,39,40,41,42,43,44,45. Intrauterine injury is induced by temporary bilateral uterine artery occlusion leading to transient systemic hypoxia-ischemia (TSHI) followed by intraamniotic injection of lipopolysaccharide (LPS)37,38,39,40,41,42,43,44,45. Subsequently, to perturb CSF dynamics and catalyze the development of hydrocephalus in the live-born pups, IVH is induced on postnatal day 1. This is accomplished with bilateral intracerebroventricular injection (ICV) of littermate lysed red blood cells (RBCs) into the lateral ventricles19,37,44. Pups are then studied as hydrocephalus develops and throughout their lifespan.